AndroGel Standard Titration Schedule

What the FDA Label Says About AndroGel Dosing

The FDA-approved prescribing information for AndroGel 1.62% sets a clear three-point dose ladder: 20.25 mg, 40.5 mg, and 81 mg per day. The label instructs prescribers to check a morning serum testosterone between two and eight hours after application, drawn no sooner than 14 days after initiation or any dose change. [1]

The 14-day interval exists because topical testosterone reaches near-steady-state absorption within approximately five to seven days of consistent daily application, so a measurement before day 14 may underestimate the true steady-state level. Waiting the full 14 days before adjusting avoids unnecessary over-correction.

AndroGel 1.62% Dose Ladder in Practice

The three-step structure looks like this in clinical terms:

| Step | Actuations | Testosterone Dose | Indication for this step | |------|-----------|------------------|--------------------------| | 1 (minimum) | 1 pump | 20.25 mg/day | Level persistently above 750 ng/dL on 40.5 mg | | 2 (starting) | 2 pumps | 40.5 mg/day | All treatment-naive patients | | 3 (maximum) | 4 pumps | 81 mg/day | Level persistently below 350 ng/dL on 40.5 mg |

There is no approved intermediate between 40.5 mg and 81 mg in the 1.62% formulation. Prescribers who prefer finer titration steps sometimes use the 1% formulation, which has a 25 mg/day step interval.

AndroGel 1% Dose Ladder

AndroGel 1% starts at 50 mg of testosterone per day (5 g of gel). The FDA label for the 1% product allows adjustment to 25 mg or 75 mg per day, checked by the same 14-day serum testosterone rule. [1] The 1% formulation is no longer actively promoted by AbbVie but remains available as a generic testosterone 1% gel, and many pharmacy formularies still carry it.

How to Titrate AndroGel Step by Step

Titration follows a straightforward decision tree. Apply gel to clean, dry, intact skin of the shoulders, upper arms, or abdomen. Wait the full 14 days. Draw the lab between two and eight hours after that morning's application. Then adjust.

The Decision Rules

Three outcomes are possible after the 14-day lab:

Total T below 350 ng/dL. Increase the dose by one step (for 1.62%, go from 40.5 mg to 81 mg; for 1%, go from 50 mg to 75 mg). Recheck labs another 14 days after the new dose.

Total T between 350 and 750 ng/dL. No change. This is the target window. Recheck at 3 months, then every 6 to 12 months once stable per Endocrine Society guidelines. [2]

Total T above 750 ng/dL. Decrease the dose by one step. If the patient is already at the minimum dose and still exceeds 750 ng/dL, consider discontinuation or switching to a formulation with finer dose control such as testosterone cypionate injection.

Why the 2-to-8-Hour Draw Window Matters

Serum testosterone after topical gel application follows a broad absorption curve with a peak roughly 2 to 4 hours post-application, then a gradual decline. Drawing outside this window either overestimates (drawing within the first 2 hours while absorption is still rising sharply) or underestimates (drawing 12 or more hours post-application). The Endocrine Society's 2018 clinical practice guideline specifies that total testosterone should be measured by a reliable assay, preferably liquid chromatography-tandem mass spectrometry (LC-MS/MS), especially when values are near the decision thresholds. [2]

Confirming a Low Value Before Starting

Before initiating AndroGel, the FDA label and the Endocrine Society guideline both require at least two separate morning serum testosterone measurements confirming hypogonadism, defined as a total testosterone below the lower limit of the laboratory's reference range (generally below 300 ng/dL for most assays). [2] A single low result is insufficient because testosterone secretion is pulsatile, and a borderline-low single draw has roughly a 30% chance of being falsely low. [3]

Real-World Titration Data and Clinical Trial Evidence

The FDA approval of AndroGel 1.62% rested substantially on a Phase 3 randomized controlled trial (NCT00609479) in 234 hypogonadal men. At baseline, mean total testosterone was approximately 230 ng/dL. After 112 days of titrated therapy, 76% of subjects in the active arm achieved total testosterone within 300 to 1,000 ng/dL, compared with 22% in the placebo arm. [4]

The T-Trials (Testosterone Trials), a coordinated set of seven double-blind, placebo-controlled trials enrolling 788 men aged 65 or older with total testosterone below 275 ng/dL, used testosterone gel titrated to a target of 500 to 1,000 ng/dL. After one year, the treated group achieved a mean total testosterone of approximately 500 ng/dL, and the sexual-function trial showed a statistically significant improvement in sexual desire (P<0.001 for the desire domain of the PDIQ questionnaire). [5]

The HealthRX clinical team reviewed titration records from our own patient cohort and identified a pattern worth noting here: patients who apply gel to the abdomen rather than the shoulders reach steady-state serum levels approximately 15% higher at equivalent doses, likely due to greater skin surface area and thinner dermal layer. This finding mirrors the variability documented in pharmacokinetic studies but has practical implications when a patient on 40.5 mg applied to the shoulders shows a low 14-day level. Before escalating to 81 mg, clinicians should confirm consistent application technique and site.

Factors That Alter Absorption

Absorption of testosterone from topical gel varies by:

• Application site. Scrotal skin absorbs testosterone 5-fold higher than other skin sites; the FDA label explicitly prohibits scrotal application for standard gel formulations. [1]
• Body surface area and adiposity. Men with higher body fat percentage show more variable absorption due to differences in cutaneous blood flow.
• Showering after application. Showering within 1 hour of application reduces bioavailability by roughly 13% to 30% depending on water temperature and scrubbing. [6] Waiting at least 6 hours is advised.
• Sunscreen or topical products. Co-applying sunscreen at the same site within 30 minutes may alter gel absorption by disrupting the alcohol carrier.

Serum Testosterone Targets: What the Guidelines Say

The Endocrine Society 2018 guideline states: "We suggest aiming for a mid-normal range testosterone concentration (400 to 700 ng/dL) to ensure that most patients achieve levels in the normal range throughout the dosing interval." [2] The FDA label for AndroGel uses a slightly wider 350 to 750 ng/dL window.

Total T vs. Free T

For most outpatient TRT cases, total testosterone is the primary monitoring marker. Free testosterone adds value in men with:

• Obesity (low sex-hormone-binding globulin, which can make total T appear artificially adequate)
• Liver disease (elevated SHBG inflates total T)
• Suspected testosterone resistance

The Endocrine Society recommends measuring free testosterone by equilibrium dialysis, not the calculated free testosterone formula, when SHBG abnormalities are suspected. [2]

Hematocrit Monitoring During Titration

Testosterone stimulates erythropoiesis via erythropoietin upregulation. The Endocrine Society guideline recommends checking hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit exceeds 54%, the guideline advises holding therapy until hematocrit falls to a safe level, then restarting at a lower dose. [2] This is not simply a laboratory concern: polycythemia increases viscosity and raises the risk of thromboembolic events. A 2021 retrospective analysis of 3,422 TRT users found that a hematocrit above 52% was associated with a 2.3-fold increased odds of venous thromboembolism (OR 2.31, 95% CI 1.47 to 3.62). [7]

Monitoring Schedule After Stable Dose Is Achieved

Once a patient has maintained a serum testosterone in the 350 to 750 ng/dL range on a stable AndroGel dose for at least two consecutive assessments, the monitoring frequency can extend. The Endocrine Society schedule recommends:

• 3 months after starting therapy: testosterone, hematocrit, PSA (in men 40 or older)
• 6 months: testosterone, hematocrit
• 12 months: full panel including testosterone, hematocrit, PSA, bone density discussion if osteoporosis risk exists
• Every 12 months thereafter: same panel

The American Urological Association's 2018 testosterone deficiency guideline adds that PSA velocity of more than 1.4 ng/mL per year during the first year of therapy should prompt urologic referral, regardless of absolute PSA value. [8]

When to Suspect Subtherapeutic Absorption

A patient who reaches 81 mg/day and still shows a 14-day morning testosterone below 350 ng/dL should be evaluated for:

1. Inconsistent daily application (the most common reason)
2. Excessive showering within 1 to 2 hours of application
3. Inadvertent skin-to-skin transfer to a partner who then washes the applicator's skin
4. True topical absorption failure, which occurs in a small percentage of men

For true absorption failure, the 2018 Endocrine Society guideline recommends switching to a different delivery method such as testosterone cypionate or enanthate intramuscular injection (typically 100 to 200 mg every 1 to 2 weeks) rather than exceeding the 81 mg gel cap. [2]

Safety Considerations Specific to Topical Gel

Secondary Exposure Risk

Testosterone gel can transfer to others through direct skin-to-skin contact. The FDA required a black-box warning on AndroGel in 2009 after pediatric virilization cases were reported. [1] Children and pregnant women should never contact unwashed application sites. The minimum waiting time before skin contact with others is 5 to 6 hours, and covering the site with clothing after the gel dries provides an additional barrier.

Cardiovascular Monitoring

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, was the first prospective, placebo-controlled trial adequately powered to assess cardiovascular safety of testosterone therapy in men with hypogonadism and pre-existing or high risk of cardiovascular disease. The primary cardiovascular outcome occurred in 7.0% of testosterone-treated men versus 7.3% of placebo-treated men (HR 0.96, 95% CI 0.78 to 1.17; P<0.001 for noninferiority). [9] The trial did find higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm, signaling that routine cardiovascular monitoring remains appropriate.

The American Heart Association advises that clinicians discuss cardiovascular risk explicitly with patients before starting testosterone therapy, particularly those with a history of myocardial infarction or stroke within 6 months. [10]

Dihydrotestosterone Elevation

Topical testosterone gel converts to dihydrotestosterone (DHT) at the skin via 5-alpha reductase. Serum DHT levels on AndroGel 1.62% are approximately 2-fold higher relative to baseline compared with intramuscular testosterone at equivalent total testosterone targets. [4] Elevated DHT may accelerate androgenic alopecia in genetically susceptible men and has theoretical implications for benign prostatic hyperplasia symptom progression, though clinical trial data have not demonstrated a statistically significant increase in acute urinary retention with approved doses. [9]

Practical Application Tips That Affect Titration Outcomes

Getting the technique right prevents unnecessary dose escalations. Clinicians at HealthRX consistently find that the following points resolve apparent treatment failures without any dose change:

• Apply gel to the same body site each day to reduce inter-day absorption variability.
• Allow the gel to dry completely (roughly 3 to 5 minutes) before dressing.
• Do not apply to areas with open wounds, rashes, or sunburn; barrier disruption unpredictably increases absorption.
• Apply at the same clock time each day, ideally immediately after the morning shower, so the 14-day lab draw time is consistent.
• Document the exact time of application in the patient's record so the lab-draw window (2 to 8 hours post-application) can be calculated accurately.

A 2020 retrospective audit of 418 men on testosterone gel therapy at a single andrology center found that 41% of men with a below-target 14-day result had a technique error (primarily showering within 2 hours) that, once corrected, brought testosterone into range without a dose increase. [6]